Jie Li

US Patent:

6548499, Apr 15, 2003

Filed:

Oct 20, 2000

Appl. No.:

09/622423

Inventors:

Kenneth G. Carson - Needham MA
David Thomas Connor - Ann Arbor MI
Jie Jack Li - Ann Arbor MI
Joseph Edwin Low - Brighton MI
Jay R. Luly - Wellesley MA
Steven Robert Miller - Ann Arbor MI
Bruce David Roth - Plymouth MI
Bharat Kalidas Trivedi - Farmington Hills MI

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 31495

US Classification:

514249, 544353, 544356

Abstract:

Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohns disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimers disease, graft versus host reaction, allograft rejections, or allergic diseases.

US Patent:

6869958, Mar 22, 2005

Filed:

Aug 5, 2003

Appl. No.:

10/634181

Inventors:

Jie Jack Li - Ann Arbor MI, US

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K031/519
C07D471/04

US Classification:

514258, 544279

Abstract:

This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof,.

US Patent:

8586030, Nov 19, 2013

Filed:

Mar 8, 2013

Appl. No.:

13/791313

Inventors:

Niven Rajin Narain - Cambridge MA, US
Jie Li - Miami FL, US
Kathryn J. Russell - New York NY, US
Indushekhar Persaud - Homestead FL, US

Assignee:

University of Miami - Miami FL

International Classification:

A61K 38/43

US Classification:

424 941

Abstract:

Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

US Patent:

20030004172, Jan 2, 2003

Filed:

Feb 13, 2002

Appl. No.:

10/075073

Inventors:

William Harter - Chelsea MI, US
Jie Li - Ann Arbor MI, US
Daniel Ortwine - Saline MI, US
Kevon Shuler - Chelsea MI, US
Wen-Song Yue - Ypsilanti MI, US

International Classification:

A61K031/522
A61K031/519
C07D491/02
C07D473/02

US Classification:

514/260100, 514/263340, 514/263330, 514/265100, 544/256000, 544/267000, 544/271000, 544/280000

Abstract:

Selective MMP-13 inhibitors are fused pyrimidinones of the formula or a pharmaceutically acceptable salt thereof, wherein: W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical X is O, S, SO, SO, NR, or CH; B is O or NR; or A and B are taken together to form —C≡C—; R, R, and Rare hydrogen, alkyl, alkenyl, alkynyl, (CH)aryl, (CH)cycloalkyl, C-Calkanoyl, or (CH)heteroaryl; Rand Rare hydrogen, alkyl, alkenyl, alkynyl CN, NO, NRR, (CH)cycloalkyl, (CH)aryl, or (CH)heteroaryl; Rmay further be halo; n is an integer of from 0 to 5; and Rand Rwhen taken together with a nitrogen to which they are both attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted; with the proviso that Rand Rare not both selected from hydrogen and C-Calkyl.

US Patent:

20030220355, Nov 27, 2003

Filed:

Apr 16, 2003

Appl. No.:

10/417073

Inventors:

Bernard Gaudilliere - Nanterre, FR
Henry Jacobelli - Paray Vieille Poste, FR
Catherine Kostlan - Saline MI, US
Jie Li - Ann Arbor MI, US
Wen-Song Yue - Ann Arbor MI, US

International Classification:

A61K031/517
C 07D 4 3/02
C07D239/72

US Classification:

514/266200, 514/266300, 544/284000, 544/286000

Abstract:

A compound selected from those of formula (I): wherein: X, X, and X, represent N or —CRin which Ris as described in the description, Grepresents a group selected from those of formulae (i/a) and (i/b): in which R, R, and Rare as defined in the description, Grepresents a group selected from carbon-carbon triple bond, —CH C CH—, C O, C S, S(O)in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i/c): in which Yrepresents O, S, —NH or —Nalkyl, and Yrepresents O, S, —NH or —Nalkyl, n is an integer from 0 to 6 inclusive, and m is an integer from 0 to 7 inclusive, Zrepresents —CRRwherein Rand Rare as defined in the description, A represents a ring system, Rrepresents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of formula (i/d): in which p, Z, B, q and Gare as defined in the description and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix mettaloprotease.

US Patent:

20040043983, Mar 4, 2004

Filed:

Aug 5, 2003

Appl. No.:

10/634182

Inventors:

Jie Li - Ann Arbor MI, US

International Classification:

C07D471/02
C07D487/02
A61K031/53
A61K031/519
A61K031/4745

US Classification:

514/210210, 544/184000, 514/243000, 514/249000, 514/248000, 514/264100, 514/300000, 544/236000, 544/279000, 544/350000, 546/122000

Abstract:

This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R, Q, Y, Y, U, U, U, R, and Rare as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

US Patent:

20060040957, Feb 23, 2006

Filed:

Feb 8, 2002

Appl. No.:

10/071032

Inventors:

Richard Dyer - Ann Arbor MI, US
William Harter - Chelsea MI, US
James Hicks - Chelsea MI, US
Adam Johnson - Ann Arbor MI, US
Jie Li - Ann Arbor MI, US
William Roark - Ann Arbor MI, US
Kevon Shuler - Chelsea MI, US

International Classification:

A61K 31/519
C07D 498/04

US Classification:

514259200, 544278000

Abstract:

Selective MMP-13 inhibitors are bicyclic pyrimidines of the Formula I or a pharmaceutically acceptable salt thereof, wherein Ris hydrogen or alkyl; R, R, and Rinclude hydrogen, halo, alkyl, C≡C(CH)aryl, COalkyl, CO(CH)aryl, COHN alkyl, and CONH(CH)aryl; and X is O, S, SO, SO, CH, C═O, CHOH, NH, or NR. A compound of Formula I, or a pharmaceutically acceptable salt thereof, is useful for treating cancer or arthritis.

US Patent:

20090318527, Dec 24, 2009

Filed:

Feb 11, 2009

Appl. No.:

12/369659

Inventors:

Howard Sard - Arlington MA, US
Yiliang Zhang - Lowell MA, US
Jie Li - Baltimore MD, US
Louis Shuster - Brookline MA, US
Bryan Roth - Durham NC, US
Niels Jensen - Carrboro NC, US

International Classification:

A61K 31/404
C07D 209/14

US Classification:

514415, 548491

Abstract:

Novel indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

Address:

3282 Honeysuckle Dr, Ann Arbor, MI 48103

Phone:

7349951023

VIN:

WBAVA33597KX77252

Make:

BMW

Model:

3 SERIES

Year:

2007